Holen Sie sich die Stockscreener-App
25.11
3.97%
0.9246
Schlusskurs vom Vortag:
$24.19
Offen:
$24.41
24-Stunden-Volumen:
608.85K
Relative Volume:
0.20
Marktkapitalisierung:
$1.59B
Einnahmen:
$16.10M
Nettoeinkommen (Verlust:
$-198.97M
KGV:
-7.215
EPS:
-3.4809
Netto-Cashflow:
$-183.99M
1W Leistung:
+1.86%
1M Leistung:
+39.49%
6M Leistung:
-8.98%
1J Leistung:
+65.90%
1-Tages-Spanne:
$24.00
$25.34
1-Wochen-Bereich:
$24.00
$25.82
52-Wochen-Spanne:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Firmenname
Uniqure Nv
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
25.23 | 1.53B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
437.26 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.22 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.30 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.35 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.01 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Mizuho | Neutral → Outperform |
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure Nv Aktie (QURE) Neueste Nachrichten
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati - AD HOC NEWS
What Just Happened with uniQure's Earnings and FDA Update - Kavout
What Caused uniQure's Dramatic Stock Plunge - Kavout
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
Mizuho downgrades UniQure NV (QURE) - MSN
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
UBS Group AG Buys 286,465 Shares of uniQure N.V. $QURE - MarketBeat
uniQure N.V.Ordinary Shares (NQ: QURE - The Chronicle-Journal
RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE) - Stock Titan
Tejara Capital Ltd Takes $1.01 Million Position in uniQure N.V. $QURE - MarketBeat
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
What Triggered uniQure's Sudden Stock Plunge - Kavout
uniQure NV(QURE) Stock Options Chain | Quotes & News - Moomoo
uniQure N.V. (NASDAQ: QURE) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Is uniQure N.V. (QURE) A Good Stock To Buy Now? - Insider Monkey
Uniqure Insider Sold Shares Worth $1,127,500, According to a Recent SEC Filing - marketscreener.com
uniQure (QURE) CMO sells 45,000 shares under 10b5-1 plan, exercises options - Stock Titan
uniQure NV | SCHEDULE 13G: Others - Moomoo
State Street (QURE) affiliates disclose 3.6% ownership, 2.26M shares - Stock Titan
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play - Seeking Alpha
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
Nan Fung Trinity HK Ltd. Purchases New Holdings in uniQure N.V. $QURE - MarketBeat
UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed - Stock Titan
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
UniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029 - MSN
uniQure N.V. (QURE) Stock Analysis: A Potential Upside of 64% Amidst Promising Gene Therapy Innovations - DirectorsTalk Interviews
(QURE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UniQure (QURE) Q1 2026 Loss Of US$53.5m Tests Bullish Growth Narrative - Sahm
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $25 to $37 - 富途牛牛
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - 富途牛牛
uniQure Q1 Earnings Call Highlights - Yahoo Finance
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Finanzdaten der Uniqure Nv-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure Nv-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
May 08 '26 |
Sale |
25.06 |
45,000 |
1,127,500 |
169,669 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):